Angeles Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$468K Buy
16,651
+2,378
+17% +$63.3K 0.03% 241
2025
Q4
$355K Buy
14,273
+2,847
+25% +$71.8K 0.02% 266
2025
Q3
$291K Sell
11,426
-507
-4% -$12.5K 0.02% 261
2025
Q2
$289K Buy
11,933
+753
+7% +$17.6K 0.02% 264
2025
Q1
$283K Sell
11,180
-7,499
-40% -$196K 0.02% 228
2024
Q4
$496K Buy
18,679
+2,882
+18% +$78.2K 0.04% 144
2024
Q3
$457K Buy
15,797
+4,217
+36% +$123K 0.04% 141
2024
Q2
$324K Buy
11,580
+2,239
+24% +$61.6K 0.03% 166
2024
Q1
$259K Sell
9,341
-5,566
-37% -$154K 0.03% 186
2023
Q4
$429K Sell
14,907
-239
-2% -$7.22K 0.05% 122
2023
Q3
$502K Sell
15,146
-1,183
-7% -$41.8K 0.07% 91
2023
Q2
$599K Sell
16,329
-1,176
-7% -$45.8K 0.08% 97
2023
Q1
$714K Buy
17,505
+2,141
+14% +$92.5K 0.11% 92
2022
Q4
$787K Buy
15,364
+2,442
+19% +$117K 0.14% 86
2022
Q3
$565K Buy
12,922
+2,105
+19% +$102K 0.11% 89
2022
Q2
$567K Sell
10,817
-858
-7% -$43.7K 0.11% 96
2022
Q1
$604K Buy
+11,675
New +$606K 0.11% 98

Other funds holding PFE

Angeles Wealth Management's PFE Position: Q1 2026 in Review

Angeles Wealth Management increased its Pfizer (PFE) stake by 17% in Q1 2026, buying an estimated $63.3K and bringing the position to 16,651 shares worth $468K. The position accounts for 0.03% of the portfolio, ranked #241.

Angeles Wealth Management first reported a position in PFE in Q1 2022 and has held it in 17 quarters since. The position peaked at $787K in Q4 2022. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Angeles Wealth Management held 16,651 shares of Pfizer worth $468K as of Q1 2026.
  • Angeles Wealth Management bought 2,378 Pfizer shares in Q1 2026, an estimated $63.3K.
  • Pfizer made up 0.03% of Angeles Wealth Management's portfolio in Q1 2026, its #241 holding.
  • Angeles Wealth Management first reported a position in Pfizer in Q1 2022 and has held it in 17 quarters since.
  • Angeles Wealth Management's Pfizer position peaked at $787K in Q4 2022.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Angeles Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.